Information for the public Information for the public

Patient safety

Home >> Information for the public >> Patient safety

You will be able to receive an explanation and fully understand and think about the clinical research before deciding whether or not to agree to participate in the exam. If you want, you can discuss it with your family or with your researchers.

Research subjects ' information

After you have decided to participate in a clinical study, you will only participate if you have voluntarily provided your written consent. Of course, you may decide not to participate in this clinical study. If you decide not to participate, your accessibility to treatment will not be affected, and there is no penalty.

Studies are important to prove the safety and effectiveness of new drugs. There is no guarantee that the treatment will be successful. Therefore, subjects must fully understand the potential discomfort, side effects, and risks associated with the study.

Researchers will do their best to avoid such risks.

Matters concerning collection, storage, and disposal of human-derived water

Human body derivatives (tissues, blood, etc.) collected for the purpose of the test will be conducted by cancer genome analysis. The human derivatives collected and cancer genome analysis information will be stored in a way that is not directly identifiable. These samples and personal information collected within the retention period may be provided to researchers other than the research team or used for secondary research purposes. Human derivatives will be disposed of according to the standards and methods of article 13 of the Waste Management Act.

The management of human-derived and cancer genome information is thoroughly monitored by the IRB; the K-master project coordinators will oversee monitoring and deliberations. Personal identification information collected will be used only for the purpose of connecting you with the samples and clinical materials that are obtained due to research and are not directly used or required for research.

Your personal information will be used until the purpose of the research is achieved.
Any data collected are maintained in accordance with privacy laws.

Confidentiality of personal information and records

Your records will be kept confidential as long as you are participating in this study, and your records will remain confidential in the event that the results of the study are written, published, or announced in a report.

Elimination of clinical Research

The decision to participate must be made voluntarily. Even after participating in a clinical study, you can cancel your participation at any time and you will incur no disadvantage in doing so. You will also be able to continue receiving a known treatment after canceling your clinical research involvement for the following reasons.

Compensation measures in the event of damage

During the clinical study period, we will make every effort to keep you safe. If a significantly hazardous case occurs, we will take quick and appropriate action to minimize the potential damage. If you believe you have been involved in a clinical study, please contact your doctor or your research staff.

Voluntary participation/withdrawal

As mentioned earlier, you may or may not participate in a clinical study. You can also stop participating in clinical studies at any time. Even if you decide not to participate in a clinical study or discontinue at any point, no disadvantage will be incurred and you will not be subject to any loss of profit that you were originally entitled to.

If you want to stop clinical research, please tell your doctor orally or in writing. If new information is collected that may affect your decision of whether to continue to participate in clinical studies, the test doctor will inform you or your agent in a timely manner.

Participant Instruction

After you have decided to participate in a clinical study, you will only participate if you have voluntarily provided your written consent. Of course, you may decide not to participate in this clinical study. If you decide not to participate, your accessibility to treatment will not be affected, and there is no penalty.

Studies are important to prove the safety and effectiveness of new drugs. There is no guarantee that the treatment will be successful. Therefore, subjects must fully understand the potential discomfort, side effects, and risks associated with the study.

Researchers will do their best to avoid such risks.

Matters concerning collection, storage, and disposal of human-derived water

Human body derivatives (tissues, blood, etc.) collected for the purpose of the test will be conducted by cancer genome analysis. The human derivatives collected and cancer genome analysis information will be stored in a way that is not directly identifiable. These samples and personal information collected within the retention period may be provided to researchers other than the research team or used for secondary research purposes. Human derivatives will be disposed of according to the standards and methods of article 13 of the Waste Management Act.

The management of human-derived and cancer genome information is thoroughly monitored by the IRB; the K-master project coordinators will oversee monitoring and deliberations. Personal identification information collected will be used only for the purpose of connecting you with the samples and clinical materials that are obtained due to research and are not directly used or required for research.

Your personal information will be used until the purpose of the research is achieved.
Any data collected are maintained in accordance with privacy laws.

Confidentiality of personal information and records

Your records will be kept confidential as long as you are participating in this study, and your records will remain confidential in the event that the results of the study are written, published, or announced in a report.

Elimination of clinical Research

The decision to participate must be made voluntarily. Even after participating in a clinical study, you can cancel your participation at any time and you will incur no disadvantage in doing so. You will also be able to continue receiving a known treatment after canceling your clinical research involvement for the following reasons.

Compensation measures in the event of damage

During the clinical study period, we will make every effort to keep you safe. If a significantly hazardous case occurs, we will take quick and appropriate action to minimize the potential damage. If you believe you have been involved in a clinical study, please contact your doctor or your research staff.

Voluntary participation/withdrawal

As mentioned earlier, you may or may not participate in a clinical study. You can also stop participating in clinical studies at any time. Even if you decide not to participate in a clinical study or discontinue at any point, no disadvantage will be incurred and you will not be subject to any loss of profit that you were originally entitled to.

If you want to stop clinical research, please tell your doctor orally or in writing. If new information is collected that may affect your decision of whether to continue to participate in clinical studies, the test doctor will inform you or your agent in a timely manner.

Participant Instruction

After you have decided to participate in a clinical study, you will only participate if you have voluntarily provided your written consent. Of course, you may decide not to participate in this clinical study. If you decide not to participate, your accessibility to treatment will not be affected, and there is no penalty.

Studies are important to prove the safety and effectiveness of new drugs. There is no guarantee that the treatment will be successful. Therefore, subjects must fully understand the potential discomfort, side effects, and risks associated with the study.

Researchers will do their best to avoid such risks.

Matters concerning collection, storage, and disposal of human-derived water

Human body derivatives (tissues, blood, etc.) collected for the purpose of the test will be conducted by cancer genome analysis. The human derivatives collected and cancer genome analysis information will be stored in a way that is not directly identifiable. These samples and personal information collected within the retention period may be provided to researchers other than the research team or used for secondary research purposes. Human derivatives will be disposed of according to the standards and methods of article 13 of the Waste Management Act.

The management of human-derived and cancer genome information is thoroughly monitored by the IRB; the K-master project coordinators will oversee monitoring and deliberations. Personal identification information collected will be used only for the purpose of connecting you with the samples and clinical materials that are obtained due to research and are not directly used or required for research.

Your personal information will be used until the purpose of the research is achieved. Any data collected are maintained in accordance with privacy laws.

Confidentiality of personal information and records

Your records will be kept confidential as long as you are participating in this study, and your records will remain confidential in the event that the results of the study are written, published, or announced in a report.

Elimination of clinical Research

The decision to participate must be made voluntarily. Even after participating in a clinical study, you can cancel your participation at any time and you will incur no disadvantage in doing so. You will also be able to continue receiving a known treatment after canceling your clinical research involvement for the following reasons.

Compensation measures in the event of damage

During the clinical study period, we will make every effort to keep you safe. If a significantly hazardous case occurs, we will take quick and appropriate action to minimize the potential damage. If you believe you have been involved in a clinical study, please contact your doctor or your research staff.

Voluntary participation/withdrawal

As mentioned earlier, you may or may not participate in a clinical study. You can also stop participating in clinical studies at any time. Even if you decide not to participate in a clinical study or discontinue at any point, no disadvantage will be incurred and you will not be subject to any loss of profit that you were originally entitled to.

If you want to stop clinical research, please tell your doctor orally or in writing. If new information is collected that may affect your decision of whether to continue to participate in clinical studies, the test doctor will inform you or your agent in a timely manner.

Participant Instruction

After you have decided to participate in a clinical study, you will only participate if you have voluntarily provided your written consent. Of course, you may decide not to participate in this clinical study. If you decide not to participate, your accessibility to treatment will not be affected, and there is no penalty.

Studies are important to prove the safety and effectiveness of new drugs. There is no guarantee that the treatment will be successful. Therefore, subjects must fully understand the potential discomfort, side effects, and risks associated with the study.

Researchers will do their best to avoid such risks.

Matters concerning collection, storage, and disposal of human-derived water

Human body derivatives (tissues, blood, etc.) collected for the purpose of the test will be conducted by cancer genome analysis. The human derivatives collected and cancer genome analysis information will be stored in a way that is not directly identifiable. These samples and personal information collected within the retention period may be provided to researchers other than the research team or used for secondary research purposes. Human derivatives will be disposed of according to the standards and methods of article 13 of the Waste Management Act.

The management of human-derived and cancer genome information is thoroughly monitored by the IRB; the K-master project coordinators will oversee monitoring and deliberations. Personal identification information collected will be used only for the purpose of connecting you with the samples and clinical materials that are obtained due to research and are not directly used or required for research.

Your personal information will be used until the purpose of the research is achieved. Any data collected are maintained in accordance with privacy laws.

Confidentiality of personal information and records

Your records will be kept confidential as long as you are participating in this study, and your records will remain confidential in the event that the results of the study are written, published, or announced in a report.

Elimination of clinical Research

The decision to participate must be made voluntarily. Even after participating in a clinical study, you can cancel your participation at any time and you will incur no disadvantage in doing so. You will also be able to continue receiving a known treatment after canceling your clinical research involvement for the following reasons.

Compensation measures in the event of damage

During the clinical study period, we will make every effort to keep you safe. If a significantly hazardous case occurs, we will take quick and appropriate action to minimize the potential damage. If you believe you have been involved in a clinical study, please contact your doctor or your research staff.

Voluntary participation/withdrawal

As mentioned earlier, you may or may not participate in a clinical study. You can also stop participating in clinical studies at any time. Even if you decide not to participate in a clinical study or discontinue at any point, no disadvantage will be incurred and you will not be subject to any loss of profit that you were originally entitled to.

If you want to stop clinical research, please tell your doctor orally or in writing. If new information is collected that may affect your decision of whether to continue to participate in clinical studies, the test doctor will inform you or your agent in a timely manner.